T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Published in: Blood advances (2017)

A 19-year-old ataxia-telangiectasia patient with T-cell prolymphocytic leukemia harbored 2 JAK3-activating hotspot mutations.The patient suffered toxicities with chemotherapy, but demonstrated a clinical response to novel use of a JAK3 inhibitor (tofacitinib).

Keyphrases

rheumatoid arthritis
case report
acute myeloid leukemia
bone marrow
early onset
young adults
mental health
ulcerative colitis
signaling pathway
locally advanced
radiation therapy
childhood cancer